59 results

image-20150528-31337-1kdfzft
Value

Posted on 03.06.2015

How understanding breast cancer at a molecular level is revolutionizing our thinking

The evolution of past and modern therapies in breast cancer has been an inspiring illustration of the progress that has been made towards cancer cures. Breast cancer makes up a quarter of new cases worldwide and is the most common cancer in women. While the number of people with breast cancer has been increasing fewer people are dying […]

The future of medtech
Value

Posted on 18.12.2014

My MedTech predictions for 2015 and their impact on our industry

This time last year, I wrote a blogpost about the priorities MedTech Europe would be working on in 2014. This year, I’ve decided to take a different approach. Based on what I see, hear and read every day, I’ll outline what I believe to be the major medtech trends, topics and evolutions we’ll be talking […]

By Serge Bernasconi Chief Executive Officer, MedTech Europe

consumerisationofcare-blogs
Value

Posted on 03.12.2014

5 Blogs inspired by the conversation on consumerisation of care

Can MedTech compete in globalised markets? Here’s a selection of five leading views on healthcare consumarisation.
The lure of wearable technology and its application to health is tremendous- so tremendous that even the richest company on the planet-Apple, can’t resist it apparently. And so goes the recent insider news that has captured the attention of people worldwide “Apple is developing software and sensors that can predict heart attacks”. Not so fast Apple, not so fast….

patientsafety
Value

Posted on 06.11.2014

Europe’s wound care gap: are member states actually paying attention to what the EU is saying?

When the European Commission published its secondary report on patient safety, it made me wonder why advanced wound care is not higher on the patient safety agenda at EU and national levels? Not that it’s a competition, but the incidence of wounds in the EU is approximately 4 million (!), which is on par with cancer (3,9 mill), cerebrovascular disease (3,9 mill), and diabetes (2 mill.).

The wound care debated has progressed for sure, but there’s much more do to be done to make sure than wound care in Europe gets the attention it deserves.

The EU’s on the right track, but…

By Paul Trueman Chair, Eucomed Advanced Wound Care Sector Group; Vice-President of Market Access Smith & Nephew

patientpower
Digital

Posted on 09.10.2014

If medtech wants to start attaching things to my body outside of the clinic, we better talk

The practice of medicine is meant to keep people well or help them get well so they can live a full, productive life. Technology provides tools toward that goal. It can help relieve pain and suffering or prevent it. But too often we get so excited about technology we lose sight of what’s really important, helping human beings live better. And when it comes to the millions of people living with chronic conditions, and now “chronic cancers”, we need to really understand their lives with an illness to know how technology can help.

By Andrew Schorr Founder

Looking at evidence with the value door wide open
Value

Posted on 28.08.2014

The narrow view of medtech as a cost driver refuted… again

The prevailing thought still today is that medtech is driving rising healthcare expenditure. More and more research and publications are finding this not to be the case. The medtech industry is happy to have a fair and balanced discussion on the value of its products, but to do so, everyone must look beyond tomorrow, beyond […]

By Serge Bernasconi Chief Executive Officer, MedTech Europe

key to ostomy care
Value

Posted on 30.06.2014

It’s not sexy but we really need to understand that a bag is not just a bag

The terms “colostomy”, “ileostomy”, and “urostomy” are not well known terms to the general public outside of the patients who need these surgical procedures in order to survive. Ostomy care following surgery is not sexy and not easily discussed publicly, given that such surgeries involve changing the manner in which people eliminate fecal or urinary waste from their bodies.

By Klaus Grunau Co-Managing Director Hollister Europe Limited - Hollister

personalised medicine
Access Value

Posted on 13.05.2014

How losing the battle for access to personalised medicine can mean losing the fight for survival: The story of Patricia Garcia-Prieto

“How much is my life worth?” Patricia Garcia-Prieto, professor of Organisational Behaviour at the Solvay Brussels School of Economics and Management and a mother of six and 11-year olds has asked this question multiple times. In her video, as a patient representative on a panel, she has been vocal about this thought that passed her mind every day. […]

By Denis Horgan Executive Director, European Alliance for Personalised Medicine

more_bottom_space
Access Regulation Value

Posted on 28.04.2014

Clinical Evidence “for In Vitro Diagnostics” should be exactly that: “for IVDs”

Safe and accurate In Vitro Diagnostics (IVDs) are essential to a safe, efficient and effective healthcare system. Policymakers recognise this and that’s why they have included a clinical evidence requirement in the upcoming revision of the IVD Directive (IVDD). Because IVDs play such a pivotal role in the treatment pathway of patients, we, the IVD […]

By Serge Bernasconi Chief Executive Officer, MedTech Europe